Buti S - Search Results

1

Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature.

Mazzaschi G, Quaini F, Bersanelli M, Buti S. Mazzaschi G, et al. Among authors: buti s. Crit Rev Oncol Hematol. 2021 Apr;160:103293. doi: 10.1016/j.critrevonc.2021.103293. Epub 2021 Mar 2. Crit Rev Oncol Hematol. 2021. PMID: 33667661 Review.

2

Chronically administered immunotherapy with low-dose IL-2 and IFN-alpha in metastatic renal cell carcinoma: a feasible option for patients with a good prognostic profile.

Vaglio A, Alberici F, Maggiore U, Buti S, Potenzoni D, Passalacqua R, Buzio C. Vaglio A, et al. Among authors: buti s. Oncology. 2009;76(1):69-76. doi: 10.1159/000178810. Epub 2008 Dec 1. Oncology. 2009. PMID: 19047813

3

Changes in lymphocyte count induced by repeated cycles with low-dose interleukin-2 and interferon-α in 146 patients with renal cell carcinoma.

Buti S, Rovere RK, Donini M, Passalacqua R, Pezzuolo D, Buzio C. Buti S, et al. Tumori. 2012 Jan-Feb;98(1):45-52. doi: 10.1177/030089161209800106. Tumori. 2012. PMID: 22495701

4

Chemotherapy in metastatic renal cell carcinoma today? A systematic review.

Buti S, Bersanelli M, Sikokis A, Maines F, Facchinetti F, Bria E, Ardizzoni A, Tortora G, Massari F. Buti S, et al. Anticancer Drugs. 2013 Jul;24(6):535-54. doi: 10.1097/CAD.0b013e3283609ec1. Anticancer Drugs. 2013. PMID: 23552469 Review.

5

BOLERO-3 results: pharmacological activity or pharmacokinetic effect?

Buti S, Bersanelli M, Tiseo M, Ardizzoni A, Musolino A. Buti S, et al. Lancet Oncol. 2014 Jul;15(8):e304. doi: 10.1016/S1470-2045(14)70242-6. Lancet Oncol. 2014. PMID: 24988929 No abstract available.

6

Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy.

Bersanelli M, Buti S, Camisa R, Brighenti M, Lazzarelli S, Mazza G, Passalacqua R. Bersanelli M, et al. Among authors: buti s. Cancers (Basel). 2014 Sep 30;6(4):2035-48. doi: 10.3390/cancers6042035. Cancers (Basel). 2014. PMID: 25271833 Free PMC article.

7

Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.

Santoni M, Buti S, Conti A, Porta C, Procopio G, Sternberg CN, Bracarda S, Basso U, De Giorgi U, Rizzo M, Derosa L, Ortega C, Massari F, Milella M, Bersanelli M, Cerbone L, Muzzonigro G, Burattini L, Montironi R, Santini D, Cascinu S. Santoni M, et al. Among authors: buti s. Target Oncol. 2015 Dec;10(4):517-22. doi: 10.1007/s11523-014-0356-3. Epub 2015 Jan 6. Target Oncol. 2015. PMID: 25559290

8

Retroperitoneal cystoadenocarcinoma: a case report with a literature review.

Zanoni D, Sikokis A, Bersanelli M, Gnetti L, Buti S. Zanoni D, et al. Among authors: buti s. Acta Biomed. 2015 Apr 27;86(1):97-105. Acta Biomed. 2015. PMID: 25948035 Review.

9

Systemic adjuvant therapies in renal cell carcinoma.

Buti S, Bersanelli M, Donini M, Ardizzoni A. Buti S, et al. Oncol Rev. 2012 Oct 8;6(2):e18. doi: 10.4081/oncol.2012.e18. eCollection 2012 Oct 2. Oncol Rev. 2012. PMID: 25992216 Free PMC article. Review.

10

Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder.

Bersanelli M, Bini P, Rabaiotti E, Facchinetti F, De Filippo M, Bortesi B, Buti S, Tiseo M. Bersanelli M, et al. Among authors: buti s. Tumori. 2017 Jan 21;103(1):66-71. doi: 10.5301/tj.5000423. Epub 2015 Sep 19. Tumori. 2017. PMID: 26391764

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

304 results

Search Page